MUC1 and non-small cell lung carcinoma: TG4010, an attenuated poxvirus engineered to express MUC-1 and IL-2 prolonged the survival of patients with advanced NSCLC when administered with first-line chemotherapy and is now being tested in phase III clinical trials (43).